Additional Proxy Soliciting Materials (definitive) (defa14a)
11 July 2017 - 10:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 11, 2017
PAREXEL International Corporation
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Massachusetts
|
|
0-21244
|
|
04-2776269
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
195 West Street
Waltham, Massachusetts 02451
(Address of principal executive offices, Zip code)
(781)
487-9900
(Registrants telephone number, including area code)
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☒
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
As previously disclosed, on June 19, 2017, PAREXEL International
Corporation (the Company or PAREXEL) entered into an Agreement and Plan of Merger (the Merger Agreement) by and among the Company, West Street Parent, LLC, a Delaware limited liability company (Parent)
and West Street Merger Sub, Inc., a Massachusetts corporation and wholly-owned subsidiary of Parent (Merger Sub), with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the Merger). Parent and Merger
Sub were formed by Pamplona Investment Partners I, L.P (Pamplona).
In connection with Pamplonas efforts to obtain debt
financing to fund a portion of the amount necessary to complete the Merger and pay related fees in connection with the Merger and related transactions, the Company and Pamplona are presenting to prospective lenders certain information regarding the
Company (the Lender Presentation). The Company is filing the Lender Presentation as Exhibit 99.1 to this Current Report on Form
8-K,
which is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.1
|
Lender Presentation dated July 2017
|
Additional Information About the Proposed Transaction and Where to
Find It
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or
approval. This document relates to a proposed transaction between PAREXEL and Parent, which will become the subject of a proxy statement to be filed with the SEC by PAREXEL, and may be deemed to be solicitation material in respect of the proposed
transaction. This document is not a substitute for the proxy statement that PAREXEL will file with the SEC or any other documents that PAREXEL may file with the SEC or send to shareholders in connection with the proposed transaction. Before making
any voting decision, investors and security holders are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they
will contain important information about the proposed transaction and related matters.
Investors and security holders will be able to obtain free copies
of the proxy statement and all other relevant documents filed or that will be filed with the SEC by PAREXEL through the website maintained by the SEC at www.sec.gov.
In addition, investors and security holders will be able to obtain free copies of the proxy statement, once it is filed, from PAREXEL by accessing
PAREXELs website at www.parexel.com or upon written request to PAREXEL International Corp., Office of the Secretary, 195 West Street, Waltham, Massachusetts 02451.
Participants in the Solicitation
Parent, PAREXEL and
their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from PAREXELs shareholders in connection with the proposed transaction. Information regarding PAREXELs directors and
executive officers is contained in the proxy statement for PAREXELs 2016 Annual Meeting of Shareholders, which was filed with the SEC on October 26, 2016. You can obtain a free copy of this document at the SECs website at
www.sec.gov or by accessing PAREXELs website at www.parexel.com. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy
statement regarding the proposed transaction when it becomes available. You may obtain free copies of this document as described in the preceding paragraph.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These statements, as they relate to West Street Parent, LLC (Parent) or PAREXEL International Corporation (PAREXEL), the management of either such
company or the proposed transaction between Parent and PAREXEL, involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These statements are based on current plans, estimates and
projections, and therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Parent and PAREXEL undertake no obligation to publicly
update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Forward-looking statements are not historical facts, but rather are based on current expectations,
estimates, assumptions and projections about the business and future financial results of the pharmaceutical industry, and other legal, regulatory and economic developments. We use words such as anticipates, believes,
plans, expects, projects, future, intends, may, will, should, could, estimates, predicts, potential,
continue, guidance, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from the
results contemplated by these forward-looking statements due to a number of factors, including, but not limited to, those described in the documents PAREXEL has filed with the U.S. Securities and Exchange Commission (the SEC) as well as
the possibility that (1) Parent and PAREXEL may be unable to obtain stockholder or regulatory approvals required for the proposed transaction or may be required to accept conditions that could reduce the anticipated benefits of the merger as a
condition to obtaining regulatory approvals; (2) the length of time necessary to consummate the proposed transaction may be longer than anticipated; (3) the transaction may divert managements attention from PAREXELs ongoing
business operations; (4) the proposed transaction may involve unexpected costs; (5) the business may suffer as a result of uncertainty surrounding the proposed transaction, including difficulties in maintaining relationships with customers
or retaining key employees; (6) the parties may be unable to meet expectations regarding the timing, completion and accounting and tax treatments of the transaction; or (7) the industry may be subject to future risks that are described in
the Risk Factors section of the Annual Reports on Form
10-K,
Quarterly Reports on Form
10-Q
and other documents filed from time to time with the SEC by
PAREXEL. Neither Parent nor PAREXEL gives any assurance that either Parent or PAREXEL will achieve its expectations.
The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of PAREXEL described in the Risk Factors section of its Annual Report on Form
10-K,
Quarterly Reports on Form
10-Q
and other documents filed by PAREXEL from time to time with the SEC. All forward-looking statements included in this document are
based upon information available to Parent and PAREXEL on the date hereof, and neither Parent nor PAREXEL assumes any obligation to update or revise any such forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Date: July 11, 2017
|
|
|
PAREXEL INTERNATIONAL CORPORATION
|
|
|
By:
|
|
/s/ Josef H. von Rickenbach
|
Name:
|
|
Josef H. von Rickenbach
|
Title:
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Lender Presentation dated July 2017
|
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024